Case Report: Inotersen reintroduction after thrombocytopenia in hereditary transthyretin amyloidosis: a case series
Cesar A. Crespi, Gisela Zanga, Maria Florencia Ardanaz, Marcela Pia Chinigo, Graciana Bianco, Andrea Del Mar Ibañez Aldecoa · 2026
Read Case Report: Inotersen reintroduction after thrombocytopenia in hereditary transthyretin amyloidosis: a case series by Cesar A. Crespi, Gisela Zanga, Maria Florencia Ardanaz, Marcela Pia Chinigo, Graciana Bianco, Andrea Del Mar Ibañez Aldecoa (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13562058.txt.
Description
Cesar Crespi and co-authors report restarting a drug after a blood side effect in a 2026 case series. Inotersen treats nerve damage from hereditary transthyretin amyloidosis, a progressive disease of many organs, but it can drop platelet counts sharply, forcing pauses or a full stop. Guidance on safely restarting was scarce, so two Argentine centers reviewed their cases.
Two men with the same gene variant had opposite severity: one moderate drop after twenty-two weeks, one severe drop after sixty-five weeks with a repeat on a first restart try. After counts recovered and other causes were ruled out, both followed a structured seven-day step-up restart under close blood monitoring, then settled on dosing every two weeks. Neither had another severe drop.
Catalog record
| CREATOR | Cesar A. Crespi, Gisela Zanga, Maria Florencia Ardanaz, Marcela Pia Chinigo, Graciana Bianco, Andrea Del Mar Ibañez Aldecoa |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 19 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |